FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894522918> ?p ?o ?g. }

• W2894522918 endingPage "9" @default.
• W2894522918 startingPage "5" @default.
• W2894522918 abstract "Abstract First‐line cytoreductive drug of choice in high risk essential thrombocythemia (ET) is currently hydroxyurea, a practice based on the results of a randomized study; second‐line drugs of choice include pegylated interferon‐α, busulfan and anagrelide. Anagrelide clinical trials were pioneered by the late Murray N. Silverstein (1928‐1998) of the Mayo Clinic whose studies led to FDA approval in March 1997. The current study represents a retrospective examination of the potential impact of anagrelide therapy on survival and disease complications in ET. 1076 patients with ET were considered (median age 58 years; females 63%); risk distribution, according to the international prognostic score for ET (IPSET), was 28% high, 42% intermediate, and 30% low. Overall (OS), myelofibrosis‐free (MFFS) and thrombosis‐free survival data were compared for ET patients diagnosed before and after the 1997 FDA approval date for anagrelide; a significant difference was apparent in OS ( P = .006; HR 1.4, 95% CI 1.1‐1.7) and MFFS ( P < .001; HR 4.2, 95% CI 2.7‐6.5), in favor of patients diagnosed prior to 1997; the difference was sustained during multivariable analysis that included IPSET. Similarly stratified survival data in polycythemia vera ( n = 665) and primary myelofibrosis ( n = 1282) showed no similar impact on survival ( P = .3 and .17, respectively). The current study represents a retrospective analysis and suggests significantly decreased OS and MFFS in ET patients diagnosed after the FDA approval date of anagrelide. Whether or not anagrelide therapy was to blame for the worsening of OS and MFFS over time cannot be assumed and requires validation in a prospective study." @default.
• W2894522918 created "2018-10-05" @default.
• W2894522918 creator A5002643270 @default.
• W2894522918 creator A5008437556 @default.
• W2894522918 creator A5016216479 @default.
• W2894522918 creator A5019568458 @default.
• W2894522918 creator A5024612499 @default.
• W2894522918 creator A5058650054 @default.
• W2894522918 creator A5061275603 @default.
• W2894522918 creator A5064374340 @default.
• W2894522918 creator A5072463255 @default.
• W2894522918 creator A5079007941 @default.
• W2894522918 creator A5080232575 @default.
• W2894522918 creator A5080965667 @default.
• W2894522918 date "2018-10-17" @default.
• W2894522918 modified "2023-09-25" @default.
• W2894522918 title "Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide" @default.
• W2894522918 cites W118940326 @default.
• W2894522918 cites W1966327962 @default.
• W2894522918 cites W1985994644 @default.
• W2894522918 cites W2003597939 @default.
• W2894522918 cites W2030435811 @default.
• W2894522918 cites W2030868349 @default.
• W2894522918 cites W2039687934 @default.
• W2894522918 cites W2051259791 @default.
• W2894522918 cites W2069651950 @default.
• W2894522918 cites W2092484653 @default.
• W2894522918 cites W2107398329 @default.
• W2894522918 cites W2199176947 @default.
• W2894522918 cites W2320032845 @default.
• W2894522918 cites W2462238653 @default.
• W2894522918 cites W2532755286 @default.
• W2894522918 cites W2565781760 @default.
• W2894522918 cites W2621870355 @default.
• W2894522918 cites W2729883758 @default.
• W2894522918 cites W2749385278 @default.
• W2894522918 cites W2783496218 @default.
• W2894522918 cites W2889194299 @default.
• W2894522918 doi "https://doi.org/10.1002/ajh.25294" @default.
• W2894522918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30252953" @default.
• W2894522918 hasPublicationYear "2018" @default.
• W2894522918 type Work @default.
• W2894522918 sameAs 2894522918 @default.
• W2894522918 citedByCount "6" @default.
• W2894522918 countsByYear W28945229182020 @default.
• W2894522918 countsByYear W28945229182021 @default.
• W2894522918 countsByYear W28945229182022 @default.
• W2894522918 countsByYear W28945229182023 @default.
• W2894522918 crossrefType "journal-article" @default.
• W2894522918 hasAuthorship W2894522918A5002643270 @default.
• W2894522918 hasAuthorship W2894522918A5008437556 @default.
• W2894522918 hasAuthorship W2894522918A5016216479 @default.
• W2894522918 hasAuthorship W2894522918A5019568458 @default.
• W2894522918 hasAuthorship W2894522918A5024612499 @default.
• W2894522918 hasAuthorship W2894522918A5058650054 @default.
• W2894522918 hasAuthorship W2894522918A5061275603 @default.
• W2894522918 hasAuthorship W2894522918A5064374340 @default.
• W2894522918 hasAuthorship W2894522918A5072463255 @default.
• W2894522918 hasAuthorship W2894522918A5079007941 @default.
• W2894522918 hasAuthorship W2894522918A5080232575 @default.
• W2894522918 hasAuthorship W2894522918A5080965667 @default.
• W2894522918 hasBestOaLocation W28945229181 @default.
• W2894522918 hasConcept C126322002 @default.
• W2894522918 hasConcept C141071460 @default.
• W2894522918 hasConcept C167135981 @default.
• W2894522918 hasConcept C2776694085 @default.
• W2894522918 hasConcept C2776755627 @default.
• W2894522918 hasConcept C2778837598 @default.
• W2894522918 hasConcept C2779316324 @default.
• W2894522918 hasConcept C2780007613 @default.
• W2894522918 hasConcept C2780076729 @default.
• W2894522918 hasConcept C2780611847 @default.
• W2894522918 hasConcept C2780829020 @default.
• W2894522918 hasConcept C2781057849 @default.
• W2894522918 hasConcept C535046627 @default.
• W2894522918 hasConcept C71924100 @default.
• W2894522918 hasConceptScore W2894522918C126322002 @default.
• W2894522918 hasConceptScore W2894522918C141071460 @default.
• W2894522918 hasConceptScore W2894522918C167135981 @default.
• W2894522918 hasConceptScore W2894522918C2776694085 @default.
• W2894522918 hasConceptScore W2894522918C2776755627 @default.
• W2894522918 hasConceptScore W2894522918C2778837598 @default.
• W2894522918 hasConceptScore W2894522918C2779316324 @default.
• W2894522918 hasConceptScore W2894522918C2780007613 @default.
• W2894522918 hasConceptScore W2894522918C2780076729 @default.
• W2894522918 hasConceptScore W2894522918C2780611847 @default.
• W2894522918 hasConceptScore W2894522918C2780829020 @default.
• W2894522918 hasConceptScore W2894522918C2781057849 @default.
• W2894522918 hasConceptScore W2894522918C535046627 @default.
• W2894522918 hasConceptScore W2894522918C71924100 @default.
• W2894522918 hasIssue "1" @default.
• W2894522918 hasLocation W28945229181 @default.
• W2894522918 hasOpenAccess W2894522918 @default.
• W2894522918 hasPrimaryLocation W28945229181 @default.
• W2894522918 hasRelatedWork W1990387953 @default.
• W2894522918 hasRelatedWork W2011253478 @default.
• W2894522918 hasRelatedWork W2038488698 @default.
• W2894522918 hasRelatedWork W2059224997 @default.

• next